FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1110-1120 March 15, 2007 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts.

Methods We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival.

Results After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft–allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft–allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died.

Conclusions Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov] .)

Source Information

From San Giovanni Battista Hospital, University of Turin, Turin (B.B., M.R., L.G., R. Sorasio, P.O., S.B., M.M., A.P., M.B.); the University of Udine, Udine (F.P., R.F.); Santa Croce e Carle Hospital, Cuneo (N.M., A.G.); Santi Antonio e Biagio Hospital, Alessandria (B.A., A.L.); the Institute for Cancer Research and Treatment, Candiolo (F.C.-S., M.A.); and San Giovanni Battista Hospital and Centro Prevenzione Oncologica Regione Piemonte, Turin (I.B., G.C.) — all in Italy; and the Fred Hutchinson Cancer Research Center, University of Washington, Seattle (R. Storb).

Address reprint requests to Dr. Bruno at the Divisione Universitaria di Ematologia, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, Turin 10126, Italy, or at benedetto.bruno{at}unito.it.

Full Text of this Article

Related Letters:

Allografting or Autografting for Myeloma
van Rhee F., Crowley J., Barlogie B., Rajkumar S. V., Kyle R. A., Moreau P., Harousseau J.-L., Attal M., Bruno B., Ciccone G., Boccadoro M.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2646-2648, Jun 21, 2007. Correspondence

This article has been cited by other articles:

• Haynes, R. J., Read, S., Collins, G. P., Darby, S. C., Winearls, C. G. (2010). Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 25: 419-426 [Abstract] [Full Text]  
• Stewart, A. K., Richardson, P. G., San-Miguel, J. F. (2009). How I treat multiple myeloma in younger patients. Blood 114: 5436-5443 [Abstract] [Full Text]  
• Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., Lacy, M. Q., Lust, J. A., Reeder, C. B., Roy, V., Russell, S. J., Short, K. E. D., Stewart, A. K., Witzig, T. E., Zeldenrust, S. R., Dalton, R. J., Rajkumar, S. V., Bergsagel, P. L. (2009). Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc. 84: 1095-1110 [Abstract] [Full Text]  
• Fionda, C., Soriani, A., Malgarini, G., Iannitto, M. L., Santoni, A., Cippitelli, M. (2009). Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation. J. Immunol. 183: 4385-4394 [Abstract] [Full Text]  
• Giarin, M. M., Giaccone, L., Sorasio, R., Sfiligoi, C., Amoroso, B., Cavallo, F., Cipriani, A., Palumbo, A., Boccadoro, M. (2009). Serum Free Light Chain Ratio, Total {kappa}/{lambda} Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clin. Chem. 55: 1510-1516 [Abstract] [Full Text]  
• Stewart, A. K. (2009). Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood 113: 3135-3136 [Full Text]  
• Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., Maziarz, R. T., Chauncey, T. R., Appelbaum, F. R., Sorror, M. L., Bensinger, W., Sandmaier, B. M., Storb, R. F., Maloney, D. G. (2009). Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 113: 3383-3391 [Abstract] [Full Text]  
• Bruno, B., Rotta, M., Patriarca, F., Mattei, D., Allione, B., Carnevale-Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., Bavaro, P., Onida, F., Busca, A., Castagna, L., Benedetti, E., Iori, A. P., Giaccone, L., Palumbo, A., Corradini, P., Fanin, R., Maloney, D., Storb, R., Baldi, I., Ricardi, U., Boccadoro, M. (2009). Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 113: 3375-3382 [Abstract] [Full Text]  
• Blade, J., Rosinol, L. (2009). Changing paradigms in the treatment of multiple myeloma. haematol 94: 163-166 [Full Text]  
• Saad, A. A, Sharma, M., Higa, G. M (2009). Treatment of Multiple Myeloma in the Targeted Therapy Era. The Annals of Pharmacotherapy 43: 329-338 [Abstract] [Full Text]  
• San-Miguel, J. F., Mateos, M.-V. (2009). How to treat a newly diagnosed young patient with multiple myeloma. ASH Education Book 2009: 555-565 [Abstract] [Full Text]  
• Logan, B., Leifer, E., Bredeson, C., Horowitz, M., Ewell, M., Carter, S., Geller, N. (2008). Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials 5: 607-616 [Abstract]  
• Moreau, P., Garban, F., Attal, M., Michallet, M., Marit, G., Hulin, C., Benboubker, L., Doyen, C., Mohty, M., Yakoub-Agha, I., Leyvraz, S., Casassus, P., Avet-Loiseau, H., Garderet, L., Mathiot, C., Harousseau, J.-L., on behalf of the IFM group, (2008). Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 112: 3914-3915 [Full Text]  
• Rosinol, L., Perez-Simon, J. A., Sureda, A., de la Rubia, J., de Arriba, F., Lahuerta, J. J., Gonzalez, J. D., Diaz-Mediavilla, J., Hernandez, B., Garcia-Frade, J., Carrera, D., Leon, A., Hernandez, M., Abellan, P. F., Bergua, J. M., San Miguel, J., Blade, J., for Programa para el Estudio y la Terapeutica de l, (2008). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112: 3591-3593 [Abstract] [Full Text]  
• Rajkumar, S. V. (2008). Treatment of Myeloma: Cure vs Control. Mayo Clin Proc. 83: 1142-1145 [Full Text]  
• Lecuyer, L., Chevret, S., Guidet, B., Aegerter, P., Martel, P., Schlemmer, B., Azoulay, E. (2008). Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J 32: 748-754 [Abstract] [Full Text]  
• Gahrton, G., Bjorkstrand, B. (2008). Allogeneic transplantation in multiple myeloma. haematol 93: 1295-1300 [Full Text]  
• Ayuk, F., Perez-Simon, J. A., Shimoni, A., Sureda, A., Zabelina, T., Schwerdtfeger, R., Martino, R., Sayer, H. G., Alegre, A., Lahuerta, J.-J., Atanackovic, D., Wolschke, C., Nagler, A., Zander, A. R., San Miguel, J. F., Kroger, N. (2008). Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. haematol 93: 1343-1350 [Abstract] [Full Text]  
• San-Miguel, J., Harousseau, J.-L., Joshua, D., Anderson, K. C. (2008). Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. JCO 26: 2761-2766 [Abstract] [Full Text]  
• Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J. (2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO 26: 2171-2177 [Abstract] [Full Text]  
• Lee, S. J., Joffe, S., Artz, A. S., Champlin, R. E., Davies, S. M., Jagasia, M., Kernan, N. A., Loberiza, F. R. Jr, Soiffer, R. J., Eapen, M. (2008). Individual Physician Practice Variation in Hematopoietic Cell Transplantation. JCO 26: 2162-2170 [Abstract] [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2008). Multiple myeloma. Blood 111: 2962-2972 [Abstract] [Full Text]  
• Atanackovic, D., Cao, Y., Luetkens, T., Panse, J., Faltz, C., Arfsten, J., Bartels, K., Wolschke, C., Eiermann, T., Zander, A. R., Fehse, B., Bokemeyer, C., Kroger, N. (2008). CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. haematol 93: 423-430 [Abstract] [Full Text]  
• El-Cheikh, J., Michallet, M., Nagler, A., de Lavallade, H., Nicolini, F. E., Shimoni, A., Faucher, C., Sobh, M., Revesz, D., Hardan, I., Furst, S., Blaise, D., Mohty, M. (2008). High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. haematol 93: 455-458 [Abstract] [Full Text]  
• Bensinger, W. (2008). Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. JCO 26: 480-492 [Abstract] [Full Text]  
• Mahtouk, K., Hose, D., De Vos, J., Moreaux, J., Jourdan, M., Rossi, J. F., Reme, T., Goldschmidt, H., Klein, B. (2007). Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications. Clin. Cancer Res. 13: 7289-7295 [Abstract] [Full Text]  
• Katzel, J. A., Hari, P., Vesole, D. H. (2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 57: 301-318 [Abstract] [Full Text]  
• van Rhee, F., Crowley, J., Barlogie, B., Rajkumar, S. V., Kyle, R. A., Moreau, P., Harousseau, J.-L., Attal, M., Bruno, B., Ciccone, G., Boccadoro, M. (2007). Allografting or Autografting for Myeloma. NEJM 356: 2646-2648 [Full Text]  
• (2007). Allogeneic vs. Second Autologous Stem-Cell Transplantation for Newly Diagnosed Myeloma. JWatch Oncology and Hematology 2007: 1-1 [Full Text]  
• Antin, J. H. (2007). Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. ASH Education Book 2007: 47-54 [Abstract] [Full Text]  
• Riddell, S. R. (2007). Engineering Antitumor Immunity by T-Cell Adoptive Immunotherapy. ASH Education Book 2007: 250-256 [Abstract] [Full Text]  
• Fonseca, R. (2007). Strategies for Risk-Adapted Therapy in Myeloma. ASH Education Book 2007: 304-310 [Abstract] [Full Text]  
• Attal, M., Moreau, P., Avet-Loiseau, H., Harousseau, J.-L. (2007). Stem Cell Transplantation in Multiple Myeloma. ASH Education Book 2007: 311-316 [Abstract] [Full Text]